Pathology and management of dermatologic toxicities associated with anti-EGFR therapy

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) inhibitors are increasingly used in cancer therapy.
• Cutaneous manifestations are the most frequent adverse reactions to EGFR inhibition.
• These skin toxicities include follicular eruptions, nail disorders, xerosis, and desquamation.

Purpose of the Study:

• To highlight the importance of managing dermatologic toxicities associated with EGFR inhibitors.
• To discuss the potential role of skin toxicities as markers of treatment responsiveness.
• To emphasize the need for evidence-based guidelines for managing these adverse events.

Main Methods:

• Review of current literature on EGFR inhibitor-associated dermatologic toxicities.
• Analysis of clinical observations regarding skin manifestations and treatment outcomes.
• Discussion of the biological underpinnings of EGFR function in epithelial tissues.

Main Results:

• Cutaneous adverse events are common and varied, including follicular eruptions, nail changes, xerosis, and desquamation.
• These dermatologic toxicities may serve as potential indicators of patient response to EGFR inhibitor therapy.
• There is a lack of established, evidence-based guidelines for managing these side effects.

Conclusions:

• Effective management of skin toxicities is critical for patients receiving EGFR inhibitors.
• Multidisciplinary collaboration between oncologists and dermatologists is essential.
• Further research is needed to develop standardized approaches for characterizing and managing EGFR inhibitor-induced dermatologic toxicities.